This one-hour webinar on EGPA, led by 3 EGPA experts, will address the most current information on the diagnosis, treatment initiation and long-term monitoring of this rare eosinophilic disorder. As EGPA affects many organ systems, a wide range of clinicians may be involved in the diagnosis and management of these patients. Faculty will review the clinical manifestations of EGPA from both rheumatologic and pulmonary perspectives, including how EGPA is similar to and differs from other vasculitides. Greater understanding of this disease has led to the development and approval of mepolizumab, the first agent specifically indicated for EGPA; additional agents are under phase 2 and 3 investigation. Patient cases will help clinicians apply the foundational information to clinical practice.
This educational activity is supported by an educational grant from GlaxoSmithKline.